ANNEE 2018

Publié le 16/01/2020 à 10h51 (mis à jour le 16/01/2020 à 12h08)

Bouquet É, Star K, Jonville-Béra AP, Durrieu G. Pharmacovigilance in pediatrics.Therapie. 2018 ;73:171-180.

Bouvenot G, Sassard J, Montastruc JL. Pour une utilisation optimale des associations fixes de médicaments. Recommandations de prescription. Bull. Acad. Natle Méd. 2017 ;201,41-44.

Couderc S, Lapeyre-Mestre M, Bourrel R, Carle P, Montastruc JL, Sommet A. Infectious risk of biological drugs versus traditional systemic treatments in moderate to severe psoriasis : a cohort analysis in the French insurance database. Fundam Clin Pharmacol. 2018 ;4:436-449.

Defer G, Le Caignec F, Fedrizzi S, Montastruc F, Chevanne D, Parienti JJ, Peyro-Saint-Paul L. Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study) : study protocol for a randomized controlled trial.Trials. 2018 ;19:174.

Diaz H, Bagheri H, Palmaro A, Rousseau V, Bourrel R, Montastruc JL, Birebent J. Patterns of direct oral anticoagulant drug prescription in France in 2010-2013 : a study in the Midi-Pyrénées area. Eur J Clin Pharmacol. 2018 ;74:945-951.

Driot D, Figuet L, Birebent J, Coste S, Durrieu G, Jacquot J, Bismuth M. Satisfaction of a pharmacovigilance declaration support network in general practice. Therapie. 2018 ;73:483-493.

Durrieu G, Maupiler M, Rousseau V, Chebane L, Montastruc F, Bondon-Guitton E, Montastruc JL. Frequency and Nature of Adverse Drug Reactions Due to Non-Prescription Drugs in Children : A Retrospective Analysis from the French Pharmacovigilance Database. Paediatr Drugs. 2018 ;20:81-87.

El Chaer G, Lapeyre Mestre M. Tramadol : la crise des opioïdes de l’Afrique. Revue Prescrire. 2018 ;418:631.

Foch C, Araujo M, Weckel A, Damase-Michel C, Montastruc JL, Benevent J, Durrieu G, Lacroix I. In utero drug exposure and hearing impairment in 2-year-old children A case-control study using the EFEMERIS database. Int J Pediatr Otorhinolaryngol. 2018 ;113:192-197.

Kaguelidou F, Kassai Koupai B, Durrieu G. Pediatric pharmacology.Therapie. 2018 ;73:111-112.

Khouri C, Lepelley M, Roustit M, Montastruc F, Humbert M, Cracowski JL. Comparative safety of drugs targeting the nitric oxide pathway in pulmonary hypertension : a mixed approach combining a meta-analysis of clinical trials and a disproportionality analysis from the WHO pharmacovigilance database. Chest. 2018 ;154:136-147.

Mahé J, de Campaigno EP, Chené AL, Montastruc JL, Despas F, Jolliet P. Pleural adverse drugs reactions and protein kinase inhibitors : Identification of suspicious targets by disproportionality analysis from VigiBase. Br J Clin Pharmacol. 2018 ;84:2373-2383.

Montastruc F, Bénard-Laribière A, Noize P, Pambrun E, Diaz-Bazin F, Tournier M, Bégaud B, Pariente A. Antipsychotics use : 2006-2013 trends in prevalence and incidence and characterization of users. Eur J Clin Pharmacol. 2018 ;74:619-626.

Montastruc F, Benevent J, Touafchia A, Chebane L, Araujo M, Guitton-Bondon E, Durrieu G, Arbus C, Schmitt L, Begaud B, Montastruc JL. Atropinic (Anticholinergic) Burden in Antipsychotic-Treated Patients. Fundam Clin Pharmacol. 2018 ;32:114-119.

Montastruc F, Bagheri H, Lacroix I, Damase-Michel C, Chebane L, Rousseau V, Jouanjus E, Lapeyre-Mestre M, Durrieu G, Montastruc JL. Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP® : A Comparison with Classical Methods of Reporting. Drug Saf. 2018 ;41:511-514.

Montastruc F, Benevent J, Rousseau V, Durrieu G, Sommet A, Montastruc JL. Risk of Diabetes with Fibrates and Statins : a pharmacoepidemiological study in Vigibase®. Fundam Clin Pharmacol. 2018 Aug 11. doi : 10.1111/fcp.12406. [Epub ahead of print]

Montastruc F, Benevent J, Chebane L, Rousseau V, Durrieu G, Sommet A, Montastruc JL. Vomiting and constipation associated with tramadol and codeine : a comparative study in VigiBase®. Eur J Clin Pharmacol. 2018 Aug 10. doi : 10.1007/s00228-018-2536-z. [Epub ahead of print].

Montastruc F, Khosrow-Khavar F, de Germay S, Renoux C, Rousseau V, Durrieu G, Montastruc M, Rascol O, Sommet A, Lapeyre-Mestre M, Benevent J, Montastruc JL. Tamoxifen and the risk of Parkinsonism : a case/non-case study. Eur J Clin Pharmacol. 2018 ;74:1181-1184.

Moulis F, Rousseau V, Chebane L, Gouverneur A, Gaboriau L, Faillie JL, Durrieu G, Montastruc F, Montastruc JL. Serious adverse drug reactions with sacubitril/valsartan Entresto® : a French pharmacovigilance survey. Eur J Clin Pharmacol. 2018 ;74:983-84.

Moulis F, Durrieu G, Masmoudi K, Gervoise Boyer M, Rocher F, Montastruc F, Montastruc JL. Medication errors with tramadol drops in children. Eur J Clin Pharmacol. 2018 ;74:247-248.

Moulis F, Durrieu G, Lapeyre-Mestre M. Off-label and unlicensed drug use in children population. Therapie. 2018 ;73:135-149.

Nguyen TTH, Roussin A, Rousseau V, Montastruc JL, Montastruc F. Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus : A Pharmacoepidemiological–Pharmacodynamic Study in VigiBase. Drug Safety. 2018.

Nguyen KD, Nguyen PT, Nguyen HA, Roussin A, Montastruc JL, Bagheri H, Olsson S. Overview of Pharmacovigilance System in Vietnam : Lessons Learned in a Resource-Restricted Country. Drug Saf. 2018 ;41:151-159.

Perez C, Olivier P, Lortal B, Duranton S, Montastruc JL, Colin AL, Toulza E, Becker M, Hamy L, Crepin S, Roussillon C, Gimbert A, Petitpain N, Salvo F. Detection of drug safety signals from clinical trials data : Role of SUSARs. Pharmacol Res. 2018 ;131:218-223.

Revet A, Montastruc F, Raynaud JP, MD, Baricault B, Montastruc JL, Maryse Lapeyre-Mestre M. Trends and Patterns of Antidepressant Use in French Children and Adolescents From 2009 to 2016. A Population-Based Study in the French Health Insurance Database. Journal of Clinical Psychopharmacology. 2018 ;38:327-335.

Reynolds E, Guénette L, Lexchin J, Cassels A, Wilkes MS, Durrieu G, Beaulieu MD, Mintzes B. Reconciling a "pleasant exchange" with evidence of information bias : A three-country study on pharmaceutical sales visits in primary care. Health Policy. 2018 ;122:250-255.

Rwagitinywaa J, Sommet A, Palmaro A, Montastruc JL, Lapeyre-Mestre M. Utilization and costs of HIV antiretroviral drugs in Europe during thelast ten years : Impact of generic antiretroviral drugs on cost reduction. Health Policy. 2018 ;122:237-242.

Rwagitinywa J, Lapeyre-Mestre M, Bourrel R, Montastruc JL, Sommet A. Comparison of adherence to generic multi-tablet regimens versus brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients. Fundam Clin Pharmacol. 2018 Mar 5. doi : 10.1111/fcp.12363. [Epub ahead of print]

Wadelius M, Eriksson N, Kreutz R, Bondon-Guitton E, Ibañez L, Carvajal A, Lucena MI, Sancho Ponce E, Molokhia M, Martin J, Axelsson T, Kohnke H, Yue QY, Magnusson PKE, Bengtsson M, Hallberg P ; EuDAC. Sulfasalazine-induced agranulocytosis is associated with the human leukocyte antigen locus. Clin Pharmacol Ther. 2017 Aug 1. doi : 10.1002/cpt.805. [Epub ahead of print]